Fig. 2From: Anti-BCMA CAR T administration in a relapsed and refractory multiple myeloma patient after COVID-19 infection: a case reportCytokine release syndrome course and recovery: temperature, inflammatory and cytokine values from CAR T cell administration through 30 days post CAR T cell administration, CRS course (shaded) days 1–6Back to article page